Focusing on industry hotspots, Frost & Sullivan's Life Sciences division has prepared and is in the process of publishing the 'Blue Book on the Current State and Development Trends of the Gene Therapy Industry'. The aim is to conduct an in-depth analysis of the gene therapy field, providing a comprehensive exposition from multiple dimensions such as technological development, application areas, marketed products, R&D status, patient needs, capital enthusiasm, industry structure, etc. It tracks the development context of the industry and technology, explores the huge potential for industry development, and analyzes the driving factors behind market development.
The Life Sciences Practice of Frost & Sullivan cordially invites gene therapy companies to participate in the Blue Book, to jointly discuss the development direction and prospects of the field of gene therapy.
The Frost & Sullivan Life Sciences Practice will hold an online launch event for the 'Blue Book on the Current State and Development Trends of the Gene Therapy Industry' in September. The event will be simultaneously pushed through the Frost & Sullivan WeChat official account and multiple media platforms. Stay tuned!
1
Research content
1) Gene therapy can correct defective genes, opening up new avenues for disease treatment. By sorting out the basic concepts, development history, and application value of gene therapy, this paper presents the general situation of gene therapy.
2) Gene therapy has the characteristic of high technical barriers, but after long-term development, related technologies have been continuously optimized and upgraded. By analyzing gene editing technology, therapeutic delivery system technology, and new technologies in the field of gene therapy, the research and development challenges and industrialization barriers of gene therapy are presented.
3) As an emerging treatment method that can alter human genetic information, the safety and product stability of gene therapy require high attention. By summarizing and analyzing domestic and international gene therapy regulatory policies, this paper mainly elaborates on the gene therapy regulatory systems of China, the United States, Japan, the European Union, and other countries or regions, providing information references for those interested in the field of gene drugs.
4) There are already some products in the field of gene therapy that have been approved for market launch, and the development of gene therapy products for numerous indications is in full swing. The clinical value of gene therapy in the field of refractory diseases is becoming increasingly prominent. By analyzing global and Chinese market launch products and research pipelines for gene therapy, this report presents the popular indications for gene therapy, the use of vector mediators, and the enthusiasm for clinical trial registration, among other aspects, to gain insights into the current development status and competitive landscape of the gene therapy industry.
5) The field of gene therapy has received continuous favor from the capital market in recent years, and the injection of capital will continue to accelerate the research and development and market launch of products in this area. By analyzing the capital market performance of gene therapy companies over the past five years, identifying market driving factors, and predicting future industry development trends.
6) Numerous enterprises have flocked into the field of gene therapy, and competition in the sector has become increasingly fierce. Technological innovation, differentiated business layout, and expansion of indications have become the core drivers for competitors. By analyzing the core technologies, business layout, and product pipeline information of some companies in the gene therapy field, this paper presents the differentiated competitive advantages of these companies.
2
Participation value
1) The 'Blue Book on the Current Situation and Development Trends of the Gene Therapy Industry' will be simultaneously released on the official Frost & Sullivan public account and multiple media platforms. Relevant companies are invited to participate in an online press conference to share industry and company progress, showcase differentiated features, and enhance their exposure in the capital market.
2) Cover hundreds of millions of customers, seamlessly integrating media, funds, banking, and brokerage communication channels. With over 5,000 high-quality media resources, effective deployment and promotion strategies can be carried out with precise placement.
3) Based on a mature industry analysis model, covering the core elements of market analysis, presenting a comprehensive and in-depth understanding of the industry, disseminating new concepts, and jointly exploring value enhancement paths with gene therapy companies.
4) Share industry insights and deepen corporate image through online or offline activities such as roundtable discussions, themed salons, and video live broadcasts related to the field of gene therapy organized by Frost & Sullivan.
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and the cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life science industry. The Life Sciences Practice has a wide range of corporate clients in China and has established a vast customer network over the past 20 years, accumulating a wealth of project experience in various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
2023 Frost & Sullivan New Investment Conference
PHDI 2023
